True Cancer Detection is Here with Molecular MRI
Changing suspicion into certainty.
Imagion Biosystems is leading the way in molecular MRI technology to help clinicians detect cancer earlier and with greater precision, leading to timely intervention.
Earlier, Clearer, More Confident Detection
Imagion Biosystems is advancing MagSense® mMRI — the first molecular MRI technology to integrate bio-safe magnetic nanoparticles with targeting molecules that selectively attach to cancer biomarkers.
Now preparing for Phase II clinical trials, MagSense® mMRI goes beyond improving resolution by detecting HER2+ breast cancer tumor signals as small as 1–2 mm, about one-tenth the size the current standard of care can detect.
This molecular precision, combined with MRI’s anatomical detail, delivers clearer, more confident imaging to support earlier, more definitive diagnosis when treatment can have the greatest impact.
How does MagSense® imaging technology work?
How is MagSense® better than other imaging methods?
How will MagSense® change cancer detection?
Clinical Utility of MagSense®
HER2+ BREAST CANCER
Each year in the U.S., about 400,000 patients are diagnosed with HER2-positive breast cancer — an aggressive form that accounts for 1 in 5 breast cancer cases.
MagSense® HER2 imaging is designed to help clinicians see what ultrasound might miss — highlighting cancerous nodes with targeted precision.
PROSTATE CANCER
Each year in the U.S., over a million men undergo biopsies, many unnecessarily, due to the limitations of current imaging.
MagSense® PSMA imaging utilizes the same PSMA-specific targeting molecule as PET tracers but without the need for radiation, enabling MRI to non-invasively detect prostate cancer and guide precision biopsies.
OVARIAN CANCER
Ovarian cancer is often found too late — 75% of cases are diagnosed at advanced stages, and nearly two-thirds of patients lose their battle.
MagSense® FR imaging targets folate receptors linked to ovarian cancer, offering the chance to detect disease earlier, when more treatment options are available.
MagSense® HER2 Imaging Agent Clinical Study
Imagion Biosystems is now preparing for Phase II clinical trials evaluating the MagSense® HER2 imaging agent — designed to help detect the spread of HER2-positive breast cancer to regional lymph nodes without the need for invasive biopsies.
Our Phase II study will assess the diagnostic performance of MagSense® in identifying nodal metastases, while optimizing MRI protocols and timing. We are also measuring concordance with current standards of care and continuing to evaluate safety in a broader patient population.
Looking to make a difference? Let’s get connected!
We respect your inbox. You’ll only hear from us when we have meaningful updates to share.